This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
IntroductionThe objective of this study was to examine the impact of ventricular assist device support as a bridge to hearttransplantation in children with end-stage heartfailure. Patients were divided into two groups: with pre transplant ventricular assist device (VAD) support and without VAD support.
The Resynchronization–Defibrillation for Ambulatory HeartFailure Trial (RAFT; NCT00251251 ) demonstrated a greater 5-year mortality benefit for patients receiving cardiac-resynchronization therapy (CRT) compared to those receiving implantable cardioverter–defibrillators (ICDs). Secondary outcomes were experienced by 77.7%
RELIEVE-HF investigators evaluated the efficacy and safety of the V-wave interatrial shunt system in patients with heartfailure. The primary endpoint was a composite of all-cause mortality, left ventricular assist device (LVAD)/hearttransplantation, HF hospitalizations, worsening HF, and KCCQ score changes. Atlanta, GA.
Background Belt electrode skeletal muscle electrical stimulation (B-SES) is an emerging therapy anticipated to yield more favorable outcomes than conventional neuromuscular electrical stimulation (NMES), owing to its larger stimulation area. However, information on its efficacy and safety in patients with heartfailure remains limited.
CMS has reviewed the CardiAMP HeartFailure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP HeartFailure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heartfailure : heartfailure with reduced ejection fraction (HFrEF) and heartfailure with preserved ejection fraction (HFpEF).
These methods only alleviate symptoms of heartfailure and myocardial ischemia and improve patients' quality of life by partially restoring myocardial reperfusion. It has become an urgent task for clinical medicine to seek new and better treatment.
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heartfailure : heartfailure with reduced ejection fraction (HFrEF) and heartfailure with preserved ejection fraction (HFpEF).
After struggling with heartfailure for the first months of his life, doctors told his parents that Zeke would need a hearttransplant immediately. Within one day, our hearttransplant team performed the transplant surgery. Now Zane, 6, and Zeke, 5, are living lives the odds said were unlikely.
The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heartfailure (ADHF) who are unresponsive to standard medical therapy. I am excited to be able to include the advanced heartfailure patients in the trial," commented Dr. Grafton.
Arrhythmias can lead to cardiac arrest (CA) and heartfailure. When intractable, hearttransplant (HTX) can become the only viable treatment. This rare, high-risk cohort has not been reported as a distinct group.
The implantation of left ventricular assist devices (LVADs) has been increasing, with good long-term results, in parallel with a growing population with advanced heartfailure (HF). However, in some European countries, LVADs are still underused, with one of the main issues being the patient's late referral.
Getty Images milla1cf Wed, 02/21/2024 - 19:10 February 21, 2024 — Ochsner Children's Hospital , ranked among the top hospitals in the nation for pediatric cardiology and congenital heart surgery, is raising awareness of the need for more pediatric-specific heart devices.
Objective The role of hyperuricaemia as a prognostic maker has been established in chronic heartfailure (HF) but limited information on the association between plasma uric acid (UA) levels and central haemodynamic measurements is available. UA) was used to estimate the effect on outcome associated with a 10% increase in UA levels.
Aims Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heartfailure (HF). Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for hearttransplantation (HTx).
Pediatric hearttransplantation has long been hailed as a life-saving intervention for children suffering from end-stage heartfailure. While the procedure offers hope, the long-term outcomes for these young patients remain suboptimal due to allograft rejection and graft failure.
BACKGROUND:In hearttransplant recipients, right ventricular (RV) dysfunction may occur for a variety of reasons. Whether RV dysfunction in the stable phase after hearttransplantation is associated with long-term adverse outcomes is unknown. years after hearttransplantation were included.
THE TEXAS HEART INSTITUTE 2024 milla1cf Tue, 02/13/2024 - 17:56 February 13, 2024 — Pediatric hearttransplantation has long been hailed as a life-saving intervention for children suffering from end-stage heartfailure.
Circulation: HeartFailure, Ahead of Print. Centers performing at least 1 hearttransplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among 3 cohorts: admissions to non-ATCs, admissions to ATCs, and transfers to ATCs.
Hearttransplant rates were low but increased slightly in 2020 for patients without CHD, with DV and SV CHD patients showing fluctuating rates peaking in 2018 and 2019, then declining in 2020. Cardiogenic shock rates were highest among SV-CHD patients, with significant fluctuations, followed by DV-CHD patients.
Venn diagram of iron deficiency (ID) according to various definitions and associated outcomes. Abstract Aims There is uncertainty about the definition of iron deficiency (ID) and the association between ID and prognosis in patients with advanced heartfailure. Non-scaled VENN diagram.
Knowledge and application of European Society of Cardiology/HeartFailure Association (ESC/HFA) guidelines in the management of advanced heartfailure (HF). Respondents were categorized into heartfailure cardiologists (HFCs), general cardiologists (GCs), and other participants (OPs). of HFCs, 19.6%
Circulation: HeartFailure, Ahead of Print. BACKGROUND:In 2018, an algorithm-based allocation system for hearttransplantation (HT) was implemented in France. The cumulative incidence of waitlist mortality estimated with competing risk analysis and incidence of transplantation were compared between diagnosis groups.
Introduction:Pediatric hearttransplant (PHT) recipient survival has improved. Yet, neurologic morbidity related to heartfailure and its treatment persist. It can affect the functional outcome, increase risk of major adverse events, prolong LOS and increase the use of rehabilitation therapies (RT).
Characteristics of heartfailure with improved ejection fraction (HFimpEF) patients and outcome comparison with heartfailure with persistently reduced ejection fraction (pHFrEF). CV mortality is the composite endpoint for CV mortality + urgent transplant + left ventricular assist device implantation.
Abstract Aims The CASTLE-HTx trial showed the benefit of atrial fibrillation (AF) ablation compared to medical therapy in decreasing mortality, need for left ventricular assist device implantation or hearttransplantation (HTx) in patients with end-stage heartfailure (HF).
Journal of the American Heart Association, Volume 13, Issue 24 , December 17, 2024. Primary outcomes included changes in Kansas City Medical Optimization score, left ventricular ejection fraction, and cardiovascular eventfree survival (unplanned HF hospitalization, left ventricular assist device /hearttransplant, or death).
The highly positive outcomes observed in primate models highlight the potential of this strategy. Heart attacks typically kill millions of cardiac muscle cells, leaving the heart in a weakened state. Cardiovascular diseases are still among the top causes of death worldwide, and especially prevalent in developed countries.
Abstract Aim Cardiac resynchronization therapy (CRT) is a cornerstone in the management of chronic heartfailure in patients with a broad or paced QRS. However, data on long-term outcome after upgrade to CRT are scarce. The secondary endpoint was first heartfailure admission. ml/min/1.73 m ml/min/1.73 m
Circulation: HeartFailure, Ahead of Print. BACKGROUND:Right ventricular dysfunction (RVD) is common in patients with heartfailure with reduced ejection fraction, and it is associated with poor prognosis. Plasma levels of FMOD and FBLN5 were significantly associated with patient outcomes (P=0.005;P=0.004).
We collected demographic, pre-procedural, procedural, and outcome-related variables. The association between a lower rate of MAE and EMB persisted in the multivariate model when those with hearttransplant who had EMB were compared to those without hearttransplant who did not have EMB p=0.001. were females.
Hearttransplantation remains a vital treatment for end-stage heartfailure, yet the scarcity of suitable donor hearts makes the treatment unavailable to many patients in critical need. Addressing this critical barrier could potentially improve post-transplantoutcomes and make older donor hearts a viable option.
A study published in JACC has compared the phenotypic expression and clinical outcomes in patients with arrhythmogenic cardiomyopathy [2]. Heartfailure, hearttransplantation and death by cardiac causes were more often seen in individuals with biventricular phenotype compared to isolated left or right ventricular phenotype.
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) use to provide hemodynamic support for acute myocardial infarction has grown exponentially, is associated with poor outcomes, and is under active clinical investigation, yet the mechanistic effect of VA-ECMO on myocardial damage in acute myocardial infarction remains poorly understood.
Investigators assessed if empagliflozin could lower the risk of hospitalization for heartfailure (HF) or death from cardiovascular disease (CVD). The percent change from baseline in fasting triglycerides (TG) at six months served as the primary outcome measure.
So she went back in 4 weeks and this time saw another doctor who asked her to stop the inhalers and suggested that it could be her heart and organised a chest X-ray and blood tests. Medications that improve quality of life in heartfailure for example include diuretics.
He was transitioned to oral heartfailure medications and discharged home slightly over one week after presentation. He was readmitted a few weeks later for a heartfailure exacerbation, diuresed, and discharged again. The last information available is that the patient was undergoing hearttransplant evaluation.
a privately held company dedicated to advancing the treatment of heartfailure ( HF ) at the intersection of digital health and medtech, today announced Premarket Approval (PMA) from the U.S milla1cf Mon, 06/24/2024 - 20:21 June 24, 2024 — Endotronix, Inc. ,
Circulation: HeartFailure, Ahead of Print. Background:Black hearttransplant patients are at higher risk of acute rejection (AR) and death than White patients. The primary composite outcome occurred in 43% and 55% of Black patients at 1 and 2 years, compared with 23% and 27% in White patients,P<0.001.
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)
BackgroundThe extent to which sex, racial, and ethnic groups receive advanced heart therapies equitably is unclear. Our primary outcome measures were the number of LVAD and HT procedures per 1000 adults with HFrEF. The main exposures were sex, race, ethnicity, and age.
BNP, CMR-LVEF and SUVmax in FDG-PET: independent predictors of outcome in a contemporary cardiac sarcoidosis population remaining robust in subgroup subanalysis. Here, we describe baseline characteristics at presentation along with prognosis and predictors of outcome in a sizable and deeply phenotyped contemporary cohort of CS patients.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content